Podcast #271 · 7 Nov 2025
How Biomarkers Enhance Precision Medicine in Non-Muscle Invasive Bladder Cancer
- Bacillus Calmette-Guérin (BCG)
- Cystoscopy
- Urologic Oncology
- Artificial Intelligence (AI)
- Pathology
- Clinical Trials
- Biomarkers
- Non-Muscle Invasive Bladder Cancer (NMIBC)
- 2025 NMIBC Creator Weekend™
- Carcinoma in Situ (CIS)
As new genetic and AI-powered tools emerge for bladder cancer screening, are we getting closer to reducing the need for invasive cystoscopies? In part five of the 2025 BackTable NMIBC Creator Weekend™ series, host Dr. Vignesh Packiam engages in an insightful discussion with Dr. Sarah Psutka from the University of Washington and Dr. Katie Murray from NYU about the complexities and potential benefits of using biomarkers in non-muscle invasive bladder cancer (NMIBC).
This podcast is supported by